Pharmacological inhibition of 5-lipoxygenase accelerates and enhances fracture-healing

Journal of Bone and Joint Surgery

Volumn 91, Issue 11, 2009, Pages 2653-2665

  Cottrell, Jessica A ^a   O'Connor, J Patrick ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; BROXURIDINE; CELECOXIB; COLLAGEN TYPE 10; COLLAGEN TYPE 2; CYCLOOXYGENASE 2; DOCEBENONE; MESSENGER RNA; OSTEOPONTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARACHIDONIC ACID METABOLISM; ARTICLE; BIOMECHANICS; BONE RADIOGRAPHY; BONE REGENERATION; CARTILAGE CELL; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; ENCHONDRAL OSSIFICATION; ENZYME INHIBITION; EXPERIMENTAL MODEL; FEMALE; FEMUR FRACTURE; FRACTURE HEALING; GENE EXPRESSION; HYPERTROPHY; IMMUNOHISTOCHEMISTRY; MORPHOMETRICS; NONHUMAN; OSSIFICATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SPRAGUE DAWLEY RAT; SYSTEMIC THERAPY;

ANIMALS; BENZOQUINONES; BONY CALLUS; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FRACTURE HEALING; LIPOXYGENASE INHIBITORS; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES; TIME FACTORS;

EID: 70449788261     PISSN: 00219355     EISSN: None     Source Type: Journal    
DOI: 10.2106/JBJS.H.01844     Document Type: Article

References (70)

1. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev. 2004;56:387-437. (Pubitemid 39096597)
2. Tanabe T, Tohnai N. Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat. 2002;68-69:95-114 (Pubitemid 35247390)
3. Murphy RC, Gijón MA. Biosynthesis and metabolism of leukotrienes. Biochem J. 2007;405:379-95. Erratum in: Biochem J. 2007;406:527.
4. Lam BK, Austen KF. Leukotriene C4 synthase: a pivotal enzyme in cellular biosynthesis of the cysteinyl leukotrienes. Prostaglandins Other Lipid Mediat. 2002;68-69:511-520
5. Haeggström JZ, Tholander F, Wetterholm A. Structure and catalytic mechanisms of leukotriene A4 hydrolase. Prostaglandins Other Lipid Mediat. 2007;83:198-202. (Pubitemid 46661258)
6. Tsuboi K, Sugimoto Y, Ichikawa A. Prostanoid receptor subtypes. Prostaglandins Other Lipid Mediat. 2002;68-69:535-556
7. Evans JF. Cysteinyl leukotriene receptors. Prostaglandins Other Lipid Mediat. 2002;68-69:587-597
8. Tager AM, Luster AD. BLT1 and BLT2: the leukotriene B(4) receptors. Prostaglandins Leukot Essent Fatty Acids. 2003;69:123-134
9. Manigrasso MB, O'Connor JP. Accelerated fracture healing in mice lacking the 5-lipoxygenase gene. Unpublished data.
10. Simon AM, Manigrasso MB, O'Connor JP. Cyclo-oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res. 2002;17:963-976 (Pubitemid 34535133)
11. Simon AM, O'Connor JP. Dose and time-dependent effects of cyclooxygenase-2 inhibition on fracture-healing. J Bone Joint Surg Am. 2007;89:500-511 (Pubitemid 46365350)
12. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. 1999;96:7563-8. Erratum in: Proc Natl Acad Sci U S A. 1999;96:9666. (Pubitemid 29299702)
13. Jones TR, Labelle M, Belley M, Champion E, Charette L, Evans J, Ford-Hutchinson AW, Gauthier JY, Lord A, Masson P, McAuliffe M, McFarlane CS, Metters KM, Pickett C, Piechuta H, Rochette C, Rodger IW, Sawyer N, Yoyng RN, Zamboni R, Abraham WM. Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol. 1995;73:191-201. Erratum in: Can J Physiol Pharmacol. 1995;73:747.
14. Poff CD, Balazy M. Drugs that target lipoxygenases and leukotrienes as emerging therapies for asthma and cancer. Curr Drug Targets Inflamm Allergy. 2004;3:19-33. (Pubitemid 38854887)
15. Rao NL, Dunford PJ, Xue X, Jiang X, Lundeen KA, Coles F, Riley JP, Williams KN, Grice CA, Edwards JP, Karlsson L, Fourie AM. Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton. J Pharmacol Exp Ther. 2007;321:1154-1160 (Pubitemid 46762702)
16. Evans JF, Ferguson AD, Mosley RT, Hutchinson JH. What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases. Trends Pharmacol Sci. 2008;29:72-78
17. Burd TA, Hughes MS, Anglen JO. Heterotopic ossification prophylaxis with indomethacin increases the risk of long-bone nonunion. J Bone Joint Surg Br. 2003;85:700-705
18. O'Connor JP, Lysz T. Celecoxib, NSAIDs and the skeleton. Drugs Today (Barc). 2008;44:693-709.
19. Carter GW, Young PR, Albert DH, Bouska J, Dyer R, Bell RL, Summers JB, Brooks DW. 5-lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther. 1991;256:929-937
20. Müller-Peddinghaus R, Fruchtmann R, Ahr HJ, Beckermann B, Bühner K, Fugmann B, Junge B, Matzke M, Kohlsdorfer C, Raddatz S, Theisen-Popp P, Mohrs K-H. BAY X1005, a new selective inhibitor of leukotriene synthesis: pharmacology and pharmacokinetics. J Lipid Mediat. 1993;6:245-248
21. Shirumalla RK, Sharma P, Dastidar SG, Paliwal JK, Kakar S, Varshney B, Singh Saini G, Sattigeri V, Salman M, Ray A. Pharmacodynamic and pharmacokinetic characterisation of RBx 7796: a novel 5-lipoxygenase inhibitor. Inflamm Res. 2008;57:135-143
22. Alexander CL, Miller SJ, Abel SR. Prostaglandin analog treatment of glaucoma and ocular hypertension. Ann Pharmacother. 2002;36:504-511 (Pubitemid 34205326)
23. Whatling C, McPheat W, Herslöf M. The potential link between atherosclerosis and the 5-lipoxygenase pathway: investigational agents with new implications for the cardiovascular field. Expert Opin Investig Drugs. 2007;16:1879-1893
24. Hakonarson H, Thorvaldsson S, Helgadottir A, Gudbjartsson D, Zink F, Andresdottir M, Manolescu A, Arnar DO, Andersen K, Sigurdsson A, Thorgeirsson G, Jonsson A, Agnarsson U, Bjornsdottir H, Gottskalksson G, Einarsson A, Gudmundsdottir H, Adalsteinsdottir AE, Gudmundsson K, Kristjansson K, Hardarson T, Kristinsson A, Topol EJ, Gulcher J, Kong A, Gurney M, Thorgeirsson G, Stefansson K. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA. 2005;293:2245-2256 (Pubitemid 40629191)
25. Wang D, DuBois RN. Pro-inflammatory prostaglandins and progression of colorectal cancer. Cancer Lett. 2008;267:197-203. (Pubitemid 351842211)
26. The burden of musculoskeletal diseases in the United States. Rosemont, IL: American Academy of Orthopaedic Surgeons; 2008.
27. Friedlaender GE, Perry CR, Cole JD, Cook SD, Cierny G, Muschler GF, Zych GA, Calhoun JH, LaForte AJ, Yin S. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am. 2001;83 Suppl 1:S151-8.
28. Boden SD, Kang J, Sandhu H, Heller JG. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial. Spine (Phila Pa 1976). 2002;27:2662-2673 (Pubitemid 35425320)
29. Govender S, Csimma C, Genant HK, Valentin-Opran A, Amit Y, Arbel R, Aro H, Atar D, Bishay M, Börner MG, Chiron P, Choong P, Cinats J, Courtenay B, Feibel R, Geulette B, Gravel C, Haas N, Raschke M, Hammacher E, van der Velde D, Hardy P, Holt M, Josten C, Ketterl RL, Lindeque B, Lob G, Mathevon H, McCoy G, Marsh D, Miller R, Munting E, Oevre S, Nordsletten L, Patel A, Pohl A, Rennie W, Reynders P, Rommens PM, Rondia J, Rossouw WC, Daneel PJ, Ruff S, Rüter A, Santavirta S, Schildhauer TA, Gekle C, Schnettler R, Segal D, Seiler H, Snowdowne RB, Stapert J, Taglang G, Verdonk R, Vogels L, Weckbach A, Wentzensen A, Wisniewski T; BMP-2 Evaluation in Surgery for Tibial Trauma (BESTT) Study Group. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am. 2002;84:2123-2134
30. Smucker JD, Rhee JM, Singh K, Yoon ST, Heller JG. Increased swelling complications associated with off-label usage of rhBMP-2 in the anterior cervical spine. Spine (Phila Pa 1976). 2006;31:2813-2819 (Pubitemid 44772783)
31. Yoshimoto T, Yokoyama C, Ochi K, Yamamoto S, Maki Y, Ashida Y, Terao S, Shiraishi M. 2,3,5-Trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone (AA861), a selective inhibitor of the 5-lipoxygenase reaction and the biosynthesis of slow-reacting substance of anaphylaxis. Biochim Biophys Acta. 1982;713:470-473
32. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, Anderson GD, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY, Isakson PC. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib). J Med Chem. 1997;40:1347-1365 (Pubitemid 27198082)
33. Bergenstock M, Min W, Simon AM, Sabatino C, O'Connor JP. A comparison between the effects of acetaminophen and celecoxib on bone fracture healing in rats. J Orthop Trauma. 2005;19:717-723 (Pubitemid 44378210)
34. Cottrell JA, Meyenhofer M, Medicherla S, Higgins L, O'Connor JP. Analgesic effects of p38 kinase inhibitor treatment on bone fracture healing. Pain. 2009;142:116-126
35. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985;150:76-85. Erratum in: Anal Biochem. 1987;163:279.
36. Morse A. Formic acid-sodium citrate decalcification and butyl alcohol dehydration of teeth and bones for sectioning in paraffin. J Dent Res. 1945;24:143-153
37. Baron R, Vigney A, Neff L, Silvergate A, Santa Maria A. Processing of undecalcified bone specimens for bone histomorphometry. In: Recker RR, editor. Bone histomorphometry: techniques and interpretation. Boca Raton: CRC Press; 1983. p 13-35.
38. Maniatopoulos C, Rodriguez A, Deporter DA, Melcher AH. An improved method for preparing histological sections of metallic implants. Int J Oral Maxillofac Implants. 1986;1:31-37
39. Balaburski G, O'Connor JP. Determination of variations in gene expression during fracture healing. Acta Orthop Scand. 2003;74:22-30. (Pubitemid 36238022)
40. Saftig P, Hunziker E, Wehmeyer O, Jones S, Boyde A, Rommerskirch W, Moritz JD, Schu P, von Figura K. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci U S A. 1998;95:13453-13458 (Pubitemid 28522993)
41. Ren W, Dziak R. Effects of leukotrienes on osteoblastic cell proliferation. Calcif Tissue Int. 1991;49:197-201.
42. Traianedes K, Dallas MR, Garrett IR, Mundy GR, Bonewald LF. 5-Lipoxygenase metabolites inhibit bone formation in vitro. Endocrinology. 1998;139:3178-3184 (Pubitemid 28512347)
43. Alini M, Marriott A, Chen T, Abe S, Poole AR. A novel angiogenic molecule produced at the time of chondrocyte hypertrophy during endochondral bone formation. Dev Biol. 1996;176:124-132 (Pubitemid 26178895)
44. Hadjiargyrou M, Ahrens W, Rubin CT. Temporal expression of the chondrogenic and angiogenic growth factor CYR61 during fracture repair. J Bone Miner Res. 2000;15:1014-1023 (Pubitemid 30350064)
45. Liang Y, Li C, Guzman VM, Evinger AJ 3rd, Protzman CE, Krauss AH, Woodward DF. Comparison of prostaglandin F2alpha, bimatoprost (prostamide), and butaprost (EP2 agonist) on Cyr61 and connective tissue growth factor gene expression. J Biol Chem. 2003;278:27267-27277 (Pubitemid 36876884)
46. Bonewald LF, Flynn M, Qiao M, Dallas MR, Mundy GR, Boyce BF. Mice lacking 5-lipoxygenase have increased cortical bone thickness. Adv Exp Med Biol. 1997;433:299-302.
47. Myers LK, Bhattacharya SD, Herring PA, Xing Z, Goorha S, Smith RA, Bhattacharya SK, Carbone L, Faccio R, Kang AH, Ballou LR. The isozyme-specific effects of cyclooxygenase-deficiency on bone in mice. Bone. 2006;39:1048-1052 (Pubitemid 44528378)
48. Grundnes O, Reikeraas O. Effects of macrophage activation on bone healing. J Orthop Sci. 2000;5:243-247 (Pubitemid 30431800)
49. Champagne CM, Takebe J, Offenbacher S, Cooper LF. Macrophage cell lines produce osteoinductive signals that include bone morphogenetic protein-2. Bone. 2002;30:26-31. (Pubitemid 34044297)
50. Martin P, Leibovich SJ. Inflammatory cells during wound repair: the good, the bad and the ugly. Trends Cell Biol. 2005;15:599-607. (Pubitemid 41619424)
51. Chang MK, Raggatt LJ, Alexander KA, Kuliwaba JS, Fazzalari NL, Schroder K, Maylin ER, Ripoll VM, Hume DA, Pettit AR. Osteal tissue macrophages are intercalated throughout human and mouse bone lining tissues and regulate osteoblast function in vitro and in vivo. J Immunol. 2008;181:1232-1244
52. Hays PL, Kawamura S, Deng XH, Dagher E, Mithoefer K, Ying L, Rodeo SA. The role of macrophages in early healing of a tendon graft in a bone tunnel. J Bone Joint Surg Am. 2008;90:565-579 (Pubitemid 351341991)
53. Henricson A, Hulth A, Johnell O. The occurrence of accessory immunologic cells in bone induction. Clin Orthop Relat Res. 1991;264:270-277
54. Andrew JG, Andrew SM, Freemont AJ, Marsh DR. Inflammatory cells in normal human fracture healing. Acta Orthop Scand. 1994;65:462-466 (Pubitemid 24331059)
55. Oni OO. The early stages of the repair of adult human diaphyseal fractures. Injury. 1997;28:521-525
56. Giachelli CM, Lombardi D, Johnson RJ, Murry CE, Almeida M. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol. 1998;152:353-358 (Pubitemid 28106380)
57. McKee MD, Nanci A. Secretion of osteopontin by macrophages and its accumulation at tissue surfaces during wound healing in mineralized tissues: a potential requirement for macrophage adhesion and phagocytosis. Anat Rec. 1996;245:394-409. (Pubitemid 26000721)
58. Krause SW, Rehli M, Kreutz M, Schwarzfischer L, Paulauskis JD, Andreesen R. Differential screening identifies genetic markers of monocyte to macrophage maturation. J Leukoc Biol. 1996;60:540-545 (Pubitemid 26356781)
59. Duvall CL, Taylor WR, Weiss D, Wojtowicz AM, Guldberg RE. Impaired angiogenesis, early callus formation, and late stage remodeling in fracture healing of osteopontin-deficient mice. J Bone Miner Res. 2007;22:286-297 (Pubitemid 46167799)
60. Urist MR. Bone: formation by autoinduction. Science. 1965;150:893-899
61. Egermann M, Baltzer AW, Adamaszek S, Evans C, Robbins P, Schneider E, Lill CA. Direct adenoviral transfer of bone morphogenetic protein-2 cDNA enhances fracture healing in osteoporotic sheep. Hum Gene Ther. 2006;17:507-517 (Pubitemid 43794490)
62. Kawaguchi H, Nakamura K, Tabata Y, Ikada Y, Aoyama I, Anzai J, Nakamura T, Hiyama Y, Tamura M. Acceleration of fracture healing in nonhuman primates by fibroblast growth factor-2. J Clin Endocrinol Metab. 2001;86:875-880 (Pubitemid 32207509)
63. Paralkar VM, Borovecki F, Ke HZ, Cameron KO, Lefker B, Grasser WA, Owen TA, Li M, DaSilva-Jardine P, Zhou M, Dunn RL, Dumont F, Korsmeyer R, Krasney P, Brown TA, Plowchalk D, Vukicevic S, Thompson DD. An EP2 receptor-selective prostaglandin E2 agonist induces bone healing. Proc Natl Acad Sci U S A. 2003;100:6736-6740 (Pubitemid 36666649)
64. Nelson FR, Brighton CT, Ryaby J, Simon BJ, Nielson JH, Lorich DG, Bolander M, Seelig J. Use of physical forces in bone healing. J Am Acad Orthop Surg. 2003;11:344-354
65. Li M, Ke HZ, Qi H, Healy DR, Li Y, Crawford DT, Paralkar VM, Owen TA, Cameron KO, Lefker BA, Brown TA, Thompson DD. A novel, non-prostanoid EP2 receptor-selective prostaglandin E2 agonist stimulates local bone formation and enhances fracture healing. J Bone Miner Res. 2003;18:2033-2042 (Pubitemid 37377454)
66. Alkhiary YM, Gerstenfeld LC, Krall E, Westmore M, Sato M, Mitlak BH, Einhorn TA. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am. 2005;87:731-741 (Pubitemid 40489347)
67. Gutierrez GE, Edwards JR, Garrett IR, Nyman JS, McCluskey B, Rossini G, Flores A, Neidre DB, Mundy GR. Transdermal lovastatin enhances fracture repair in rats. J Bone Miner Res. 2008;23:1722-1730
68. Al-Zube L, Breitbart EA, O'Connor JP, Parsons JR, Bradica G, Hart CE, Lin SS. Recombinant human platelet-derived growth factor BB (rhPDGF-BB) and beta-tricalcium phosphate/collagen matrix enhance fracture healing in a diabetic rat model. J Orthop Res. 2009;27:1074-1081
69. Ancill RJ, Takahashi Y, Kibune Y, Campbell R, Smith JR. Randomized double-blind, placebo-controlled clinical trial of a selective 5-lipoxygenase inhibitor (AA-861) for the prevention of seasonal allergic rhinitis. J Int Med Res. 1990;18:75-88. (Pubitemid 20123933)
70. Kishikawa K, Matsunaga N, Maruyama T, Seo R, Toda M, Miyamoto T, Kawasaki A. ONO-LB-457: a novel and orally active leukotriene B4 receptor antagonist. Adv Prostaglandin Thromboxane Leukot Res. 1991;21A:407-410